FDA approves Sun's generic form of cancer drug Eloxatin

03/11/2010 | Google

The FDA approved Sun Pharmaceutical Industries' generic version of Eloxatin, a colon and rectal cancer treatment from Sanofi-Aventis. The approval allowed Sun subsidiary Caraco Pharmaceutical Laboratories to launch a 50- and a 100-milligram formulation of the drug, also known as oxaliplatin.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX